DermaVir: A plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS

Expert Review of Vaccines

Volumn 10, Issue 10, 2011, Pages 1371-1384

  Lori, Franco ^a  

^a ViroStatics Srl   (Italy)

Author keywords

AIDS; dendritic cells; DermaPrep; DermaVir; HIV; Langerhans cells; therapeutic vaccine; transdermal vaccine delivery; vaccine; virus like particles

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLASMID DNA; RECOMBINANT PROTEIN; VIRUS LIKE PARTICLE VACCINE; VIRUS RNA; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; APPLICATION SITE ERYTHEMA; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMORAL IMMUNITY; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; HUMANS; MICE; NANOMEDICINE; PLASMIDS; RABBITS; VACCINES, DNA;

EID: 80053985011     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.118     Document Type: Article

References (77)

1. Masur H, Michelis MA, Greene JB. et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N. Engl. J. Med. 305(24), 1431-1438 (1981).
2. Gottlieb MS, Schroff R, Schanker HM. et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305(24), 1425-1431 (1981).
3. Losina E, Schackman BR, Sadownik SN. et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin. Infect. Dis. 49(10), 1570-1578 (2009).
4. Lohse N, Hansen AB, Pedersen G.et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann. Intern. Med. 146(2), 87-95 (2007).
5. Gandhi RT, Zheng L, Bosch RJ. et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 7(8), pii: e1000321 (2010).
6. Hatano H, Hayes TL, Dahl V. et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J. Infect. Dis. 203(7), 960-968 (2011).
7. Hatano H, Delwart EL, Norris PJ. et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS 24(16), 2535-2539 (2010).
8. Palmer S, Maldarelli F, Wiegand A. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105(10), 3879-3884 (2008).
9. Abbott A. Therapeutic HIV vaccines show promise. Nature 466(7306), 539 (2010).
10. Routy JP, Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy 2(4), 467-476 (2010).
11. Jones T. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs 11(8), 964-970 (2010).
12. Coffin J. Persistence, resistance, diversity: insights into the HIV-host interaction. Presented at: HIV DART 2010: Frontiers in Drug Development for Antiretroviral Therapies. Los Cabos, Mexico, 7-10 December 2010.
13. Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med. 16(2), 224-227 (2010).
14. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu. Rev. Immunol. 15, 617-648 (1997).
15. Ada G. Overview of vaccines and vaccination. Mol. Biotechnol. 29(3), 255-272 (2005).
16. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 124(4), 677-681 (2006).
17. Rappuoli R. Reverse vaccinology. Curr. Opin. Microbiol. 3(5), 445-450 (2000).
18. Blazevic V, Mannik A, Malm M. et al. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)- MultiHIV DNA vaccine. AIDS Res. Hum. Retroviruses 22(7), 667-677 (2006).
19. Malm M, Sikut R, Krohn K, Blazevic V. GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model. Vaccine 25(17), 3293-3301 (2007).
20. Garcia F, Climent N, Assoumou L. et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis. 203(4), 473-478 (2011).
21. Wolff JA, Malone RW, Williams P. et al. Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1), 1465-1468 (1990).
22. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 356(6365), 152-154 (1992).
23. Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine 21(7-8), 649-658 (2003).
24. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol. Res. 42(1-3), 219-232 (2008).
25. Anderson RJ, Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25(Suppl. 2), B24-B34 (2007).
26. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J. Biomed. Biotechnol. 2010, 174378 (2010).
27. Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr. Opin. Immunol. 22(2), 264-270 (2010).
28. Lisziewicz J, Rosenberg E, Lieberman J. et al. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340(21), 1683-1684 (1999).
29. Lori F, Lewis MG, Xu J. et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 290(5496), 1591-1593 (2000).
30. Toke ER, Lorincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int. J. Pharm. 392(1-2), 261-267 (2010).
31. Lisziewicz J, Trocio J, Whitman L. et al. DermaVir: a novel topical vaccine for HIV/ AIDS. J. Invest. Dermatol. 124(1), 160-169 (2005).
32. Somogyi E, Xu J, Gudics A. et al. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine 29(4), 744-753 (2011).
33. Paavonen J, Naud P, Salmeron J. et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009).
34. Group TFIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356(19), 1915-1927 (2007).
35. Le Gall S, Erdtmann L, Benichou S. et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 8(4), 483-495 (1998).
36. Yang OO, Nguyen PT, Kalams SA. et al. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol. 76(4), 1626-1631 (2002).
37. Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. J. Virol. 76(5), 2274-2278 (2002).
38. Korber B, Brander C, Haynes BF. et al. HIV Molecular Immunology. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA (2008).
39. Sandstrom E, Nilsson C, Hejdeman B. et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis. 198(10), 1482-1490 (2008).
40. Ellenberger D, Wyatt L, Li B. et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02-AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology 340(1), 21-32 (2005).
41. Fischer W, Perkins S, Theiler J. et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 13(1), 100-106 (2007).
42. Montefiori DC, Safrit JT, Lydy SL. et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol. 75(13), 5879-5890 (2001).
43. Bellier B, Huret C, Miyalou M. et al. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine 27(42), 5772-5780 (2009).
44. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 27(12), 573-579 (2006).
45. Lisziewicz J, Gabrilovich DI, Varga G. et al. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J. Virol. 75(16), 7621-7628 (2001).
46. Boussif O, Lezoualc'h F, Zanta MA. et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA 92(16), 7297-7301 (1995).
47. Choosakoonkriang S, Lobo BA, Koe GS, Koe JG, Middaugh CR. Biophysical characterization of PEI/DNA complexes. J. Pharm. Sci. 92(8), 1710-1722 (2003).
48. von Harpe A, Petersen H, Li Y, Kissel T. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control Release 69(2), 309-322 (2000).
49. Ohana P, Gofrit O, Ayesh S. et al. Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer. Gene Ther. Mol. Biol. 8, 181-192 (2004).
50. Kantoff PW, Higano CS, Shore ND. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
51. Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods 31(3), 232-242 (2003).
52. Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin. Immunol. 12(3), 163-171; discussion 257-344 (2000).
53. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991).
54. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002).
55. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines 7(8), 1201-1214 (2008).
56. Bauer J, Bahmer FA, Worl J, Neuhuber W, Schuler G, Fartasch M. A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope. J. Invest. Dermatol. 116(2), 313-318 (2001).
57. + T cells after gene gun immunization. J. Exp. Med. 188(6), 1075-1082 (1998).
58. Powles T, Robinson D, Stebbing J. et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol. 27(6), 884-890 (2009).
59. Uglietti A, Maserati R. Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411. Expert Opin. Investig. Drugs 20(4), 559-565 (2011).
60. Calarota SA, Weiner DB, Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine 25(16), 3070-3074 (2007).
61. Cristillo AD, Lisziewicz J, He L. et al. HIV 1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology 366(1), 197-211 (2007).
62. Calarota SA, Foli A, Maserati R. et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J. Immunol. 180(9), 5907-5915 (2008).
63. Buchbinder SP, Mehrotra DV, Duerr A. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
64. Keating SM, Bejon P, Berthoud T. et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol. 175(9), 5675-5680 (2005).
65. Schnuriger A, Dominguez S, Guiguet M. et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 23(16), 2079-2089 (2009).
66. Lisziewicz J, Trocio J, Xu J.et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 19(1), 35-43 (2005).
67. Lisziewicz J, Calarota S, Banhegyi D, Lisziewicz Z, Ujhelyi E, Lori F. Single DermaVir patch treatment of HIV+ individuals induces long lasting, high magnitude and broad HIV-specific T cell responses. Presented at: CROI 2008. Boston, USA, 3-6 February 2008.
68. Lisziewicz J, Calarota S, Banhegyi D, Lisziewicz Z, Ujhelyi E, Lori F. Single DermaVir patch treatment of HIV+ individuals induces long-lasting, high-magnitude, and broad HIV- specific T cell responses. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008 (Poster #715).
69. + T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J. Immunol. 180(12), 7907-7918 (2008).
70. van Lunzen J, Pollard R, Stellbrink HJ.et al. DermaVir for initial treatment of HIV-infected subjects demonstrates preliminary safety, immunogenicity and HIV-RNA reduction versus placebo immunization. Presented at: XVIII International AIDS Conference. Vienna, Austria (2010) (Abstract #A-240-0111-12561).
71. Rodriguez B, Asmuth D, Matining R.et al. Repeated-dose transdermal administration of DermaVir, a candidate plasmid DNA-based therapeutic HIV vaccine, is safe and well-tolerated: a 61-week analysis of ACTG Study 5176. Presented at: XVIII International AIDS Conference. Vienna, Austria (2010) (Abstract # A-240-0111- 10145).
72. Katlama C, Ingrand D, Loveday C. et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA 276(2), 118-125 (1996).
73. Vidal C, Garcia F, Gatell JM. et al. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. J. Acquir Immune Defic Syndr. Hum. Retrovirol 19(1), 55-60 (1998).
74. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255), 1582-1586 (1996).
75. Davis BS, Chang GJ, Cropp B.et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75(9), 4040-4047 (2001).
76. Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis. Aquat Organ 64(1), 13-22 (2005).
77. Thacker EL, Holtkamp DJ, Khan AS, Brown PA, Draghia-Akli R. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease